Search

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

The invisible burden of the pandemic

Writing about my perspective on the COVID-19 pandemic has been on my mind for some time.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

Press Release "Crucial Directives must be revised to protect patients' interests and improve access to treatment"

This was a key message of a two-day conference, “Haematology and the next European decade”, hosted by the European Parliament and attended by doctors, researchers, parliamentarians, patients’ organisations and Commission officials.

Read more

Breakthrough results in European multicenter trial on acute promyelocytic leukemia (APL): no more chemotherapy?

APL is a rare, yet aggressive, subtype of acute myeloid leukemia (AML) characterized by a maturation arrest of white blood cell precursors in the marrow, leading to a shortage of normal white cells and platelets in the blood, which is…

Read more